Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the cancer promoting cellular micro-environment, has expanded with the incorporation if a U.S. subsidiary, Pleco Therapeutics USA, Inc., alongside the appointment of Michael Stalhamer as its President. Mr Stalhamer also serves on the global leadership team as Vice President Product Development and Regulatory Affairs.   Incorporated in Delaware, Pleco Therapeutics USA, Inc., will operat...